AAAAAA

   
Results: 1-17 |
Results: 17
INTERLEUKIN-2 AND LEUKEMIA
Authors: GOODMAN M CABRAL L CASSILETH P
Citation: M. Goodman et al., INTERLEUKIN-2 AND LEUKEMIA, Leukemia, 12(11), 1998, pp. 1671-1675
ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) RELATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL) IN A HISPANIC POPULATION
Authors: RAEZ L PATEL P RAUB W CASSILETH P
Citation: L. Raez et al., ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) RELATED PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL) IN A HISPANIC POPULATION, Blood, 90(10), 1997, pp. 3942-3942
PROGNOSTIC FACTORS FOR SURVIVAL IN ACQUIRED-IMMUNODEFICIENCY-SYNDROME(AIDS) AND NON-AIDS RELATED PATIENTS WITH PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL)
Authors: RAEZ L PATEL P RAUB W CASSILETH P
Citation: L. Raez et al., PROGNOSTIC FACTORS FOR SURVIVAL IN ACQUIRED-IMMUNODEFICIENCY-SYNDROME(AIDS) AND NON-AIDS RELATED PATIENTS WITH PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL), Blood, 90(10), 1997, pp. 3943-3943
EXPRESSION OF APOPTOSIS-REGULATORY PROTEINS BCL-2, BAX AND CASPASE-3 IN NON-HODGKINS-LYMPHOMAS - AN ECOG STUDY (E6491)
Authors: KRAJEWSKA M KRAJEWSKA S YOUNG M WELLER E NEIMAN R MEDERIOS J GLICK J VENKATRAJ U GORDON L CASSILETH P REED JC
Citation: M. Krajewska et al., EXPRESSION OF APOPTOSIS-REGULATORY PROTEINS BCL-2, BAX AND CASPASE-3 IN NON-HODGKINS-LYMPHOMAS - AN ECOG STUDY (E6491), Blood, 90(10), 1997, pp. 328-328
PHASE-I TRIAL OF DOSE-ESCALATION WITH GROWTH-FACTOR SUPPORT IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE AGGRESSIVE LYMPHOMAS - DETERMINATION OF THE MAXIMUM-TOLERATED DOSE OF PROMACE-CYTABOM
Authors: GORDON LI ANDERSEN J HABERMANN TM WINTER JN GLICK J SCHILDER RJ CASSILETH P
Citation: Li. Gordon et al., PHASE-I TRIAL OF DOSE-ESCALATION WITH GROWTH-FACTOR SUPPORT IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE AGGRESSIVE LYMPHOMAS - DETERMINATION OF THE MAXIMUM-TOLERATED DOSE OF PROMACE-CYTABOM, Journal of clinical oncology, 14(4), 1996, pp. 1275-1281
A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION ASINITIAL THERAPY FOR HIGH-RISK NON-HODGKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY
Authors: SCHENKEIN DP ROITMAN D MILLER KB MORELLI J STADTMAUER E PECORA AL CASSILETH P LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION ASINITIAL THERAPY FOR HIGH-RISK NON-HODGKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 88(10), 1996, pp. 462-462
BCL-2 FAMILY GENES, CPP32 PROTEASE, 13Q14 DELETIONS, AND IN-VITRO SENSITIVITY TO FLUDARABINE AND 2-CHLORODEOXYADENOSINE IN B-CLL - AN ECOG STUDY
Authors: KITADA S BULLRICH F KRAJEWSKI S ZAPATA J ANDERSEN J HINES J CASSILETH P CROCE CM HEED JC
Citation: S. Kitada et al., BCL-2 FAMILY GENES, CPP32 PROTEASE, 13Q14 DELETIONS, AND IN-VITRO SENSITIVITY TO FLUDARABINE AND 2-CHLORODEOXYADENOSINE IN B-CLL - AN ECOG STUDY, Blood, 88(10), 1996, pp. 2639-2639
MODULATION OF MULTIDRUG-RESISTANCE IN DE-NOVO ADULT ACUTE MYELOID-LEUKEMIA - VARIABLE EFFICACY OF REVERTING AGENTS IN-VITRO
Authors: PAIETTA E ANDERSEN J RACEVSKIS J ASHIGBI M CASSILETH P WIERNIK PH
Citation: E. Paietta et al., MODULATION OF MULTIDRUG-RESISTANCE IN DE-NOVO ADULT ACUTE MYELOID-LEUKEMIA - VARIABLE EFFICACY OF REVERTING AGENTS IN-VITRO, Blood reviews, 9(1), 1995, pp. 47-52
MINIMAL RESIDUAL DISEASE IN PATIENTS WITH HAIRY-CELL LEUKEMIA IN COMPLETE REMISSION - COMPARISON OF 2-CHLORODEOXYADENOSINE WITH 2-DEOXYCOFORMYCIN AND PREDICTION OF EARLY RELAPSE
Authors: TALLMAN M HAKIMIAN D WHEATON S KOPECKY K WOLLINS E FOUCAR K CASSILETH P HABERMANN T GREVER M PETERSON LC
Citation: M. Tallman et al., MINIMAL RESIDUAL DISEASE IN PATIENTS WITH HAIRY-CELL LEUKEMIA IN COMPLETE REMISSION - COMPARISON OF 2-CHLORODEOXYADENOSINE WITH 2-DEOXYCOFORMYCIN AND PREDICTION OF EARLY RELAPSE, Blood, 86(10), 1995, pp. 1390-1390
EXPRESSION OF BCL-2 FAMILY GENES AND IN-VITRO SENSITIVITY TO FLUDARABINE AND 2-CHLORODEOXY-ADENOSINE IN B-CLL - AN ECOG STUDY
Authors: KITADA S ANDERSEN J HINES J RAI K CASSILETH P REED JC
Citation: S. Kitada et al., EXPRESSION OF BCL-2 FAMILY GENES AND IN-VITRO SENSITIVITY TO FLUDARABINE AND 2-CHLORODEOXY-ADENOSINE IN B-CLL - AN ECOG STUDY, Blood, 86(10), 1995, pp. 2417-2417
A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL BOOD STEM-CELL (PBSC) TRANSPLANTATION AS INITIAL THERAPY FOR HIGH-RISK NON-HODSKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY
Authors: SCHENKEIN DP MILLER KB SWEET M ROSENBACH M STADTMAUER E CASSILETH P COOPER B LAZARUS HM
Citation: Dp. Schenkein et al., A PHASE-II TRIAL OF FILGRASTIM (G-CSF) SUPPORTED HIGH-DOSE SEQUENTIALCHEMOTHERAPY AND PERIPHERAL BOOD STEM-CELL (PBSC) TRANSPLANTATION AS INITIAL THERAPY FOR HIGH-RISK NON-HODSKINS LYMPHOMA(NHL) - A MULTICENTER PILOT-STUDY, Blood, 86(10), 1995, pp. 3844-3844
THE IMMUNOPHENOTYPE OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) - AN ECOG STUDY
Authors: PAIETTA E ANDERSEN J GALLAGHER R BENNETT J YUNIS J CASSILETH P ROWE J WIERNIK PH
Citation: E. Paietta et al., THE IMMUNOPHENOTYPE OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) - AN ECOG STUDY, Leukemia, 8(7), 1994, pp. 1108-1112
MULTIDRUG-RESISTANCE GENE (MDR-1) TRANSCRIPT OR CD34 ANTIGEN EXPRESSION LEVELS DO NOT PREDICT FOR COMPLETE REMISSIONS IN DE-NOVO ADULT ACUTE MYELOID-LEUKEMIA (AML) - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
Authors: PAIETTA E ANDERSEN J RACEVSKIS J BENNETT J ROWE JM CASSILETH P WIERNIK PH
Citation: E. Paietta et al., MULTIDRUG-RESISTANCE GENE (MDR-1) TRANSCRIPT OR CD34 ANTIGEN EXPRESSION LEVELS DO NOT PREDICT FOR COMPLETE REMISSIONS IN DE-NOVO ADULT ACUTE MYELOID-LEUKEMIA (AML) - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY, Blood, 84(10), 1994, pp. 10000377-10000377
EFFICACY OF CYCLOPHOSPHAMIDE (CYC) AND FLUDARABINE (FAMP) AS 1ST LINETHERAPY OF LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL) - ECOG 1491
Authors: HOCHSTER H OKEN M BENNETT J WOLF B GORDON L RAPHAEL B GENCARELLI P CASSILETH P
Citation: H. Hochster et al., EFFICACY OF CYCLOPHOSPHAMIDE (CYC) AND FLUDARABINE (FAMP) AS 1ST LINETHERAPY OF LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL) - ECOG 1491, Blood, 84(10), 1994, pp. 10000383-10000383
PHASE-II STUDY OF MENOGARIL IN PATIENTS (PTS) WITH RELAPSED REFRACTORY ACUTE MYELOID-LEUKEMIA (AML) - EST 8490
Authors: DUTCHER JP LEONG T MAKARY A PAIETTA E BENNETT J CASSILETH P WIERNIK PH
Citation: Jp. Dutcher et al., PHASE-II STUDY OF MENOGARIL IN PATIENTS (PTS) WITH RELAPSED REFRACTORY ACUTE MYELOID-LEUKEMIA (AML) - EST 8490, Blood, 82(10), 1993, pp. 10000130-10000130
MITOXANTRONE, VINBLASTINE AND CCNU (MVC) - A HIGHLY-ACTIVE REGIMEN INPOOR-PROGNOSIS HODGKINS-DISEASE (HD)
Authors: DUTCHER JP WIERNIK PH EINZIG AI CASSILETH P
Citation: Jp. Dutcher et al., MITOXANTRONE, VINBLASTINE AND CCNU (MVC) - A HIGHLY-ACTIVE REGIMEN INPOOR-PROGNOSIS HODGKINS-DISEASE (HD), Blood, 82(10), 1993, pp. 10000143-10000143
A RANDOMIZED COMPARISON OF DEOXYCOFORMYCIN (DCF) VERSUS ALPHA-2A INTERFERON (IFN) IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH HAIRY-CELL LEUKEMIA (HCL) - AN UPDATED REPORT ON THE NCI-SPONSORED INTERGROUP STUDY(SWOG, ECOG, CALGB, NCIC CTG)
Authors: GREVER M KOPECKY K HEAD D FOUCAR K CASSILETH P GOLOMB H HABERMANN T RAI K EISENHAUER E APPELBAUM F CHESON B
Citation: M. Grever et al., A RANDOMIZED COMPARISON OF DEOXYCOFORMYCIN (DCF) VERSUS ALPHA-2A INTERFERON (IFN) IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH HAIRY-CELL LEUKEMIA (HCL) - AN UPDATED REPORT ON THE NCI-SPONSORED INTERGROUP STUDY(SWOG, ECOG, CALGB, NCIC CTG), Blood, 82(10), 1993, pp. 10000199-10000199
Risultati: 1-17 |